Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by T. Decker
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
Abstract External IDs PubMed 40381382 Keywords advanced breast cancer, conditional progression-free survival, conditional survival, metastatic breast cancer, RIBANNA, ribociclib
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)☆
Statistical analysis Sample size calculation was based on the primary endpoint. Overall, 156 patients (78 in each arm) were required to detect a clinically relevant difference of 20% in the rate of stomatitis episode grade ≥2 between treatment arms at 12 weeks (40% and 20% estimated in the EVE 10mg and EVE esc arms, respectively) using a two-sided continuity-corrected χ2 test with a significance level of α = 0.20 and a power of 90%.
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study - European Journal of Cancer
Publication HistoryPublished online: April 29, 2017Accepted: March 20, 2017; Received in revised form: March 18, 2017; Received: February 27, 2017;
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
↵ ‡ Member names of the study groups are listed in supplementary Appendix, available at Annals of Oncology online . Background To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab.
PD-027BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)
PD-027BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306) S. Stintzing1, L. Fischer von Weikersthal2, T. Decker3, A. Kiani4, U. Vehling-Kaiser5, S.-E. Al-Batran6, T. Heintges7, C. Lerchenmüller8, C. Kahl9, G. Seipelt10, F. Kullmann11, M. Stauch12, J. Hielscher13, M. Lerch14, W. Scheithauer15, A. Jagenburg16, S. Held17, D. Modest18, A. Jung19, T. Kirchner19 and V.
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
Background To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab. Patients and methods CEA response assessed as the percentage of CEA decrease from baseline to nadir was evaluated for its association with tumor response and survival.
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
Background To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type mCRC receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab. Patients and Methods CEA response assessed as the percentage of CEA decrease from baseline to nadir was evaluated for its association with tumor response and survival.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with T.
Contact T., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack